FDA Approves Dostarlimab-gxly for dMMR Recurrent or Advanced Solid Tumors

On August 17, 2021, the U.S. Food and Drug Administration (FDA) approved a second indication for dostarlimab-gxly for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors—as determined by an FDA-approved test—that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.

Read the FDA announcement.

Read GlaxoSmithKline's announcement.

Posted 8/18/2021